Successful response to camrelizumab in metastatic bladder cancer: A case report.

ABSTRACT:

Background

There has been no report to use camrelizumab with chemotherapy for advanced bladder cancer patients with positive programmed death-ligand 1 (PD-L1) expression and high tumor mutational burden (TMB). More effective predictors of bladder cancer immunotherapy have yet to be explored, and the combination of multiple factors may be more predictive than a single factor.

Case summary

We report the case of a 74-year-old male patient with recurrent metastatic bladder cancer, which demonstrated positive PD-L1 expression and high TMB. The immune checkpoint inhibitor camrelizumab was administered to the patient in combination with gemcitabine and cisplatin. The patient achieved a partial response with a progression-free survival of 11 mo.

Conclusion

This is the first r

SUBMITTER: Xie C 

PROVIDER: S-EPMC8727277 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature